Navigation Links
Neura Therapeutik and AIT Laboratories Partner to Promote Pain Products
Date:9/6/2012

PRINCETON, N.J. and INDIANAPOLIS, Sept. 6, 2012 /PRNewswire/ -- Neura Therapeutik and AIT Laboratories have formed a strategic partnership to explore the possibility of co-promoting current and future analgesic products to pain specialty physicians. Under the terms of the agreement, Neura would support AIT's national sales force with its established commercial drug and development infrastructure.

In a 2011 report issued by Research and Markets, it is estimated that the U.S. market for pain management therapeutics will generate more than $40 billion annually and is expected to grow to $60 billion by 2015. This market includes treatments for a wide range of conditions including postoperative pain, cancer, arthritis, migraines and back pain. "Entering into this strategic partnership allows AIT to complement our existing laboratory testing and is consistent with AIT's position as a healthcare company offering healthcare practitioners options to help them treat patients with chronic pain," said AIT President and CEO Ron Thieme, Ph.D. AIT Laboratories is a national healthcare company specializing in compliance monitoring, forensics and clinical testing.

Neura Therapeutik is a pain specialty company led by a management team with years of experience in the analgesic market that has successfully launched blockbuster drugs such as Duragesic® and Vicodin ES®. "We are very excited about the collaboration with AIT and are confident that the efforts of their sales force will strengthen the position of our analgesic product portfolio," said Neura Therapeutik CEO John LaLota. "The addition of AIT's sales force, together with the efforts of our institutional sales force, will allow us to effectively educate pain treating physicians about the scientific value and patient benefits offered by our products and those of our co-promotion partners."

Chronic pain affects an estimated 116 million adults in the U.S. -- more than the number affected by heart disease, diabetes, and cancer combined, according to a report by the Institute of Medicine. "AIT has worked with healthcare practitioners treating chronic pain for many years and we know the challenges they sometimes face in finding relief for their patients," said Thieme. "The sophisticated data we provide from our laboratory reports coupled with information about new analgesics in the market, will give healthcare practitioners additional avenues to effectively treat their patients and improve patient outcomes."

About Neura Therapeutik:
Neura Therapeutik LLC (Neura) is a pain specialty company focused on the commercialization of innovative analgesics that address unmet needs in the marketplace. Neura is divided into two strategic business units:

  • Neura Labs, LLC – Focused on the in-licensing and launch of pharmaceutical assets where Neura's development and commercial experience can be leveraged to provide value enrichment through optimal clinical development and commercial advancement.
  • Neura Group, LLC – Focused on providing an array of commercial services and management oversight that will optimize the value of market ready/currently marketed assets.
  • Please visit neuratherapeutik.com for more information.
  • About AIT Laboratories
    AIT Laboratories, headquartered in Indianapolis, Ind., is a national healthcare company that specializes in compliance testing, forensic toxicology drug testing and clinical laboratory testing. The employee-owned company is recognized nationwide for superior customer service and quality in testing. To learn more about AIT, visit AITLABS.com; follow us on Twitter and like us on Facebook.Media Contacts:Raquel Bahamonde

    Greg GirondaAIT Laboratories

    Neura Therapeutik LLC 317-308-0064

    609-256-1942rbahamonde@aitlabs.com

    girondag@neuratherapeutik.com


    '/>"/>
    SOURCE AIT Laboratories
    Copyright©2012 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Neuralstem Announces Exercise Of Entire Over-Allotment Option By Aegis Capital Corp.
    2. Phosphagenics Appoints Neura Therapeutik as US Strategic Commercial Advisors
    3. Neura Therapeutik Forms Business Units to Pursue Analgesic Market Opportunities
    4. Seventeenth Patient Dosed in Neuralstem ALS Stem Cell Trial
    5. First Patients Dosed in Ib Phase of Neuralstems NSI-189 Trial in Major Depressive Disorder
    6. Sixteenth Patient Dosed In Neuralstem ALS Stem Cell Trial
    7. Neuralstem Updates ALS Stem Cell Trial Progress
    8. Millennium Laboratories Angela Huskey Named Industry Pain Educator of the Year by American Society of Pain Educators
    9. Nelson Laboratories to Present Latest FDA Trends at MEDevice Forum San Diego
    10. SureGene and PGXL Laboratories launch the SureGene Test for Antipsychotic and Antidepressant Response (STA2R)
    11. Millennium Laboratories Announces Landmark Pharmacogenetics Clinical Outcomes Study
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:12/7/2016)... PARK , Israel , December 7, 2016 ... today the signing of a memorandum of understanding with Korean company ... between the companies will assist in expediting Kadimastem,s entry into international ... innovative treatment for severe diseases in general and ALS and diabetes ... , , ...
    (Date:12/7/2016)... , Dec. 7, 2016 Boehringer Ingelheim ... in patients with unresectable malignant pleural mesothelioma (MPM) ... The data, presented at the 17 th ... Vienna , showed nintedanib plus pemetrexed/cisplatin ... plus pemetrexed/cisplatin, with a significantly improved PFS (9.4 ...
    (Date:12/7/2016)... , Dec. 7, 2016  Ionis Pharmaceuticals, Inc. (NASDAQ: ... will present a company overview at the BMO Capital Markets Prescriptions ... New York, NY . A live webcast of ... of the Ionis website.  The replay will be available within 48 ... ...
    Breaking Medicine Technology:
    (Date:12/7/2016)... ... 2016 , ... It is vital for any lab to secure funding, and ... team at Beckman Coulter has designed Kaluza, templates with advanced analytical tools to streamline ... operate in a GLP (Good Laboratory Practice) fashion. , With features designed to simplify ...
    (Date:12/7/2016)... ... ... came time to blow out his candles on his 14th birthday, Estefano Reano had only ... team at Joe DiMaggio Children’s Hospital surprised his family with a phone call that made ... , “He was playing at home, when we got the phone call telling us there ...
    (Date:12/7/2016)... ... ... One of two inventors from Glen Burnie, Md., has a granddaughter who ... is why the co-inventor and I have designed a new and better way to ... of the patent-pending AV-AIR, a device that serves as an alternative to conventional methods ...
    (Date:12/7/2016)... ... December 07, 2016 , ... ... that its fully redesigned website, which launched October 17, 2016, features comprehensive information ... design and easy-to-navigate layout. Visitors and patients can discover the latest clinical dermatology ...
    (Date:12/7/2016)... City, CA (PRWEB) , ... December 07, 2016 , ... ... during the holidays and winter seasons. One major study analyzing heart attacks among ... compared to August of a given year. We would all agree of course–no time ...
    Breaking Medicine News(10 mins):